Drugs / rFla-MBP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00124865 | Jul 2005 → Nov 2006 | diarrheal disease | U.S. Army Medical Research and Development Command | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rFla-MBP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00124865 ↗ |
| Known as | Recombinant Flagellin Subunit Campylobacter Vaccine | “Intranasal Recombinant Flagellin Subunit Campylobacter Vaccine (rFla-MBP) Dose-Ranging Study” NCT00124865 ↗ |
| Modality | Vaccine | “Recombinant Flagellin Subunit Campylobacter Vaccine” NCT00124865 ↗ |
| Route | Intranasal | “receive one of four intranasal rFla-MBP vaccine doses” NCT00124865 ↗ |